Answers are grounded in this paper and cite their sources.
The objective of the present study was to evaluate the expediency of the application of nano-scale silver preparations, argovit-C and vitargol, differing in concentration for the treatment of tuberculosis of the upper respiratory tract. The study was carried out based at the Karachaevo-Cherkessian TB dispensary. It has been demonstrated that the 3.3% solution of argovit-C possessed of the 100% bactericidal activity with respect to the medically-resistant mycobacteria at both maximum and minimal concentrations of isoniazid. Based on these findings, this preparation was chosen for the clinical study. It was shown to exhibit a higher therapeutic effectiveness in comparison with the standard anti-tuberculosis treatment. The authors conclude that the inhalation of the 3.3% argovit-C solution twice daily for 10 minutes during 2 months can be recommended for the local treatment of laryngeal tuberculosis.
No takes yet. Share an insight, caveat, or question.
Ураскулова et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: